LIU, XIAOQUAN

Release date:2016-05-17  Release:



LIU, XIAOQUAN

Professor of Pharmacokinetics

School of Pharmacy

Phone: 86-25-83271260

Email: liuxqcpu@163.com

Research Summary

Professor LIU’s research focuses on the PK-PD modeling and the disease progression modeling for complex diseases such as Alzheimer’s disease as well as T2DM. He recently published a paper entitled " Evaluating Alzheimers disease progression by modeling crosstalk network disruption." Aβ, tau and P-tau have been widely accepted as reliable markers for Alzheimer’s disease (AD). The crosstalk between these markers forms a complex network. AD may induce the integral variation and disruption of the network. The aim of this study was to develop a novel mathematic model based on a simplified crosstalk network to evaluate the disease progression of AD.This research evaluates the progression of AD and facilitates AD early diagnosis, which will improve our understanding of MCI-to-AD conversion mechanism.


Education

2001       Ph.D., PharmacologyChina Pharmaceutical University

1989       M.S.,  PharmacologyChina Pharmaceutical University

1984       B.S.,   PharmacyNanjing College of Pharmacy

Academic Experience

2003-      Professor of Pharmacokinetics, China Pharmaceutical University

1996-2003  Associate Professor of PharmacokineticsChina Pharmaceutical University

Awards and Honors

1998  Excellent-young-backbone teacher of Jiangsu collegesand universities.,  Education Department of Jiangsu Province

2004    The first prize of Jiangsu Scientific and Technological Progress Award,  JiangsuScience and Technology Department

2007    The second prize of National Scientific and Technological Progress Award, The State Ministry of Science and Technology 

Publications

  1. Evaluating Alzheimers disease progression by modeling crosstalk network disruption. Frontiers in Neuroscience  2016 ;9 :523

  2. A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease.

Scientific Reports, 2016 (accepted)

  1. Mechanism-based Pharmacokinetic-Pharmacodynamic Modeling of Salvianolic Acid A Effects on Plasma Xanthine Oxidase Activity and Uric Acid Levels in Acute Myocardial Infarction Rats. Xenobiotica 2016accepted

  2. A novel metabolic balance model for describing the metabolicdisruption of and interactions between cardiovascular-relatedmarkers during acute myocardial infarction  Metabolism 2013621357-1366

  3. Effects of Salvianolic Acid A on Plasma and Tissue Dimethylarginine Levels in a Rat Model of Myocardial Infarction   J Cardiovasc Pharmacol  201361482-488

  4. Relative imbalances in the expression of catechol-O-methyltransferase and cytochrome P450 in the breast cancer tissue and their association with breast carcinoma. Maturitas 2012; 72:139-145

  5. Using neural networks to determine the contribution of danshensu to its multiple cardiovascular activities in acute myocardial infarction rats. J Ethnopharmacol. 2011, 138(1):126-134

  6. Pharmacokinetic interactions induced by content variation of major water-soluble components of Danshen preparation in rats[J]. Acta Pharmacol Sin , 2010; 31(5): 638-646

  7. Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats. Pharm Res2009 ;26(8):1863-73

  1. Beneficial effects of danshensu, an active component of silvia miltiorrhiza, on homocysteine metabolism via the trans-sulphuration  pathway in rat.  Br J Pharmacol 2009;157(3):482-90

  2. Pharmacokinetics. Editor-in-Chief2015.8Phoenix Science Press